BiotechTube

LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SC

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperlipidemia

Conditions

Hyperlipidemia

Trial Timeline

Sep 1, 2011 → Jun 1, 2013

NCT ID
NCT01426412

About LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SC

LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SC is a phase 1 stage product being developed by Eli Lilly for Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01426412. Target conditions include Hyperlipidemia.

What happened to similar drugs?

8 of 20 similar drugs in Hyperlipidemia were approved

Approved (8) Terminated (2) Active (11)
✅Diet+pravastatinDaiichi SankyoApproved
✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved
✅Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved
✅Rosuvastatin (Crestor)AstraZenecaApproved
✅simvastatin + EzetimibeMerckApproved
✅Evolocumab + Statins (Cardiovascular Agents)AmgenApproved
✅atorvastatin + atorvastatin + atorvastatinPfizerApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01426412Phase 1Completed

Competing Products

20 competing products in Hyperlipidemia

See all competitors
ProductCompanyStageHype Score
DRL-17822 or placeboDr. Reddy's LaboratoriesPhase 2
32
VK2809 + PlaceboViking TherapeuticsPhase 2
32
YHP1701 + YHR1703 + YHR1704YuhanPhase 3
40
YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placeboYuhanPhase 3
40
Diet+pravastatinDaiichi SankyoApproved
43
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved
43
Pravafen + Pravastatin + FenofibrateShionogiPhase 3
40
Evacetrapib + Atorvastatin + Ezetimibe + PlaceboEli LillyPhase 3
32
exenatideEli LillyPre-clinical
26
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injectionsJiangsu Hengrui MedicinePhase 1
33
SHR-1209Jiangsu Hengrui MedicinePhase 1
29
SHR-1209 + PlaceboJiangsu Hengrui MedicinePhase 1/2
32
Rosuvastatin + AtorvastatinAstraZenecaPhase 2
35
Rosuvastatin (Crestor)AstraZenecaApproved
39
simvastatin + EzetimibeMerckApproved
43
MK-0524A + Atorvastatin + SimvastatinMerckPhase 3
40
simvastatin 20 mg/ezetimibeMerckPhase 2/3
38
Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for RosuvastatinMerckPhase 3
47
Sitagliptin + PlaceboMerckPhase 2/3
38